Breye Therapeutics
PrivateLast Round
Series A
Feb 9, 2026
Total Funding Raised
$4.1M
Company Overview
Breye Therapeutics is a biopharmaceutical company developing orally administered small-molecule therapies for the treatment of retinal vascular diseases such as diabetic retinopathy and age-related macular degeneration.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Breye Therapeutics Comparables
Compare Breye Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vantage Biosciences | 88% | |
| AltRegen | 81% | |
| Opus Genetics | 80% |
Breye Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 9, 2026 | ||||
| Seed | Nov 10, 2022 |
Key People
Founding team and executive leadership
Breye Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Fund Denmark | Seed |
| Novo Holdings | Seed |
| The Export and Investment Fund of Denmark | Seed |
| BioInnovation Institute | Seed |
| Sound Bioventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2022
$4M round led by Novo Holdings and Sound Bioventures.
Recent news
Latest coverage and updates
- is_developingSep 23, 2026
Breye Therapeutics ApS will develop danegaptide on Jul 1st '27.
Breye Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Breye Therapeutics's valuation, stock price, and market status.
Is Breye Therapeutics a public or private company?
Breye Therapeutics is a private company.
What is the current stock price of Breye Therapeutics?
Breye Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Breye Therapeutics worth (valuation)?
Valuation information for Breye Therapeutics is not publicly available.
Can I buy Breye Therapeutics stock?
Breye Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Breye Therapeutics's last funding round?
Breye Therapeutics's most recent funding round was Seed on November 10, 2022.
Who are the main investors in Breye Therapeutics?
Key investors in Breye Therapeutics include Novo Holdings, Sound Bioventures.
Will Breye Therapeutics IPO soon?
No public IPO plans have been announced for Breye Therapeutics.
How can I track Breye Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Breye Therapeutics's secondary market activity and sign up for updates.